Patent · US Active

MCL-1 antagonists

US10544131B2 · kind B2 · utility

0Cited by
4References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJul 3, 2018
Grant dateJan 28, 2020
Priority date—
Expiry dateJul 3, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D471/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Provided herein are Mcl-1 antagonist compositions and methods of treating cancer using the compositions described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.